Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort

Table 3 Variables associated with 28-day mortality in Canadian sites in ENHANCE

	Survivors Mean (SD)	Non-survivors Mean (SD)	P value*
Age – years	55.4 (17.4)	62.3 (15.4)	0.0014
Change in serum creatinine (μmol/L), pre-infusion** to day 1	2.8 (85.7)	31.0 (66.0)	0.0011
Change in platelet count (× 10⁹/L) from pre-infusion to day 1	-10.2 (47.7)	-27.6 (59.0)	0.0052
Number of organ dysfunctions per patient at baseline	3.0 (1.16)	3.4 (1.088)	0.0073
Baseline APACHE II score	24.7 (7.65)	27.4 (8.153)	0.0100
Time to treatment – hours	26.1 (11.3)	27.6 (14.0)	0.2447
Time to treatment <24 hours	80.9%	19.1%	0.1788
Time to treatment ≥24 hours	74.4%	25.6%

* P value is based on a one-sided Wilcoxon rank sums test; ** lowest creatinine recorded pre-infusion.
APACHE = Acute Physiologic and Chronic Health Evaluation; SD = standard deviation.

ISSN: 1364-8535